Roohi Mariam Peter

Cardiff

Junior Reporter at Labiotech

Journalist @Labiotech_eu | MA International Journalism @cardiffjomec | she/her

Featured in: Favicon

labiotech.eu Favicon

wetheitalians.com Favicon

hongkongbusinessreporter.com

Articles

First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field?

2 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. For the first time in 50 years, a new antibiotic has been created to tackle a drug-resistant bacteria that causes serious infections like pneumonia and sepsis.
Key cancer therapy highlights you need to know

3 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. We’re nearly halfway through 2025, and like clockwork, the American Society of Clinical Oncology (ASCO) annual summit took place from the 30th of May to the 3rd of June in Chicago this year.
Top biotech deals in May 2025

3 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. The month of May was a quieter one on the deals front compared to the past few months this year. Still, biopharmas got together to fuel the RNA and small molecule spaces.
What’s after Imaavy? Myasthenia gravis’s competitive landscape is heating up

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. Myasthenia gravis is a chronic autoimmune condition that causes muscle weakness. While there is no cure yet, there are treatments that offer symptom relief.
Biotech trends to watch in Europe through 2025 and beyond

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. The biotech industry in Europe is in a phase driven by technological advancement, investments, and evolving regulatory frameworks.
The genomics layoff wave in the US

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. Just five months into 2025, and a string of layoffs has already come down on the genomics space.
Europe’s bold move to attract America’s best biopharma minds

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. As U.S. budget cuts and freezes push healthcare and biopharma research in the States towards uncertainty, could Europe be the destination that science talent flocks towards?
Montreal’s biotech boom: 9 startups to watch in 2025

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. Montreal, the largest city in Canada’s Quebec province, has seen a boom in life sciences over the years.
Pharma giants pull back on AAV gene therapy: What’s the next big move?

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Once hailed as the solution to delivering gene therapies, adeno-associated virus (AAV) vectors have seen their star dim in recent years.
Unlocking immunity: the power of TLR agonists

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. In the vast field of immunotherapy, toll-like receptor agonists (TLR) emerged as powerful catalysts to boost the immune system.